Inotiv, Inc. (NOTV) Cash Flow Statement

The consistent gap between net income and operating cash flow indicates that the company's reported losses are not merely accounting artifacts but reflect genuine cash burn. Investors should monitor whether the inability to convert operations into positive cash flow stems from structural inefficiencies or the ongoing costs associated with integrating recent acquisitions.

The persistent negative FCF trend suggests that the business model is currently unable to self-fund its operations, necessitating reliance on external financing. This trajectory warrants caution, as the lack of positive cash generation limits management's flexibility to navigate the current biotech funding downturn.

The necessity of ongoing capital investment to maintain regulatory compliance and facility standards creates a rigid cost floor that the company cannot easily bypass. This capital intensity appears to be a significant headwind, as it forces cash outflows even during periods of operational contraction.

Such erratic swings in working capital suggest that the company's cash conversion cycle is highly sensitive to lumpy contract milestones and potential supply chain disruptions. Analysts should investigate whether these fluctuations are indicative of aggressive revenue recognition or simply the inherent nature of long-term toxicology study billing cycles.